Flowable Hemostatic Gel Cross-Linking Red Blood Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for inhibiting bleeding at surgical sites, such as suturing, manual pressure, and hemostatic devices, are ineffective for internal incisions and limited by the delivery of biopolymer-based hemostatic gel compounds to internal sites.
Innovation Solution
A flowable hemostatic gel composition comprising a biopolymer dissolved in a solvent, which cross-links with red blood cells to facilitate clot formation, and includes additional active agents like thrombin and bioadhesives, enabling direct application and effective hemostasis even in hard-to-reach areas.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional hemostatic methods (suturing, manual pressure, absorbent materials) are used, then bleeding can be controlled at accessible sites, but they are ineffective for internal incisions and hard-to-reach areas
Solution Approach 1:
The patent utilizes the flowable properties of the gel composition to enable it to be delivered through catheters or injection systems to internal surgical sites, leveraging fluid dynamics to overcome accessibility limitations of traditional mechanical hemostatic methods
Solution Approach 2:
The gel composition transitions from a flowable state during delivery to a gelated state at the target site, changing its physical parameters to achieve both deliverability to internal sites and effective hemostasis upon arrival
2Reliability
If hemostatic gel compounds are applied to internal sites, then bleeding inhibition is improved, but the ability to deliver such gel compounds to internal sites is limited
Solution Approach 1:
The composition is formulated to flow through delivery catheters using fluid pressure and flow dynamics, enabling minimally invasive delivery to internal surgical sites that were previously inaccessible to hemostatic agents
Solution Approach 2:
The gel composition maintains a flowable state during delivery through catheters, then undergoes gelation at the target site through environmental triggers or chemical reactions, enabling both deliverability and effective hemostasis
3Force
If absorbent materials like gauze and sponges are used, then temporary pressure can be applied, but effectiveness is limited after the procedure is complete
Solution Approach 1:
The gel composition transitions from a flowable state during application to a gelated state at the target site, providing sustained hemostasis that persists after the procedure without requiring continued external pressure or manual intervention
Solution Approach 2:
The gel composition autonomously forms a hemostatic barrier at the surgical site through self-gelation, eliminating the need for continuous external pressure application and providing lasting hemostasis without secondary removal
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The flowable gel composition effectively inhibits bleeding by rapidly forming clots and adhering to tissues, providing sustained hemostasis and accelerating healing without the need for secondary removal, while being biodegradable and safe for in vivo use.
Implementation Method 1
a biopolymer of the flowable hemostatic gel composition cross-links with red blood cells at the site to facilitate clot formation at the site
Implementation Method 2
The flowable gel composition effectively inhibits bleeding by rapidly forming clots and adhering to tissues
Data Source
AI summary
A flowable hemostatic gel composition is provided for use at a site of a defect within a biological tissue. The flowable hemostatic gel composition includes a flowable gel solution that includes a biopolymer dissolved in a first solvent. The biopolymer is configured to cross-link with red blood cells at the site to facilitate clot formation at the site. The flowable hemostatic gel composition also includes at least one additional active agent.